{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002506981,0.0002191143,0.0005312125,0.0001444598,0.0001400998,0.000006745116,0.0001966482,0.00006353194,0.0004282535],"category_scores_gemma":[0.0003103979,0.0001556888,0.00014039,0.0004538572,0.0003135396,0.00008999289,0.00008162531,0.000306417,0.000002981893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005389652,"about_ca_system_score_gemma":0.001963933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004478533,"about_ca_topic_score_gemma":0.002284975,"domain_scores_codex":[0.9979746,0.00008559709,0.0007658639,0.0002981783,0.0006693095,0.0002064907],"domain_scores_gemma":[0.9987739,0.0001411026,0.0003512115,0.0003656502,0.000165348,0.0002027957],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2154208,0.2583049,0.02523774,0.0007695388,0.003967792,0.0001444732,0.1006345,0.001046772,0.3162251,0.005676565,0.01255156,0.06002026],"study_design_scores_gemma":[0.8767185,0.0270406,0.002101446,0.0003052093,0.001307175,0.00002378665,0.0006416313,0.0006949311,0.07976052,0.006078401,0.004984427,0.0003434393],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916713,0.00008820234,0.000007797281,0.004609172,0.0006034026,0.002461282,0.0002870666,0.00001835682,0.0002534576],"genre_scores_gemma":[0.9975341,0.00001179336,0.0003400987,0.0004917294,0.0003988218,0.0002405837,0.00003071304,0.0000256488,0.0009265093],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6612976,"threshold_uncertainty_score":0.6770232,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04450204486330388,"score_gpt":0.3536828405025805,"score_spread":0.3091807956392766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}